SLN Stock Analysis: Silence Therapeutics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 491m USD | 12M Return: 77.1% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 3.36M
Qual. Beats: 0
Rev. Trend: -64.4%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality
Silence Therapeutics plc (NASDAQ: SLN) is a London-headquartered biotechnology company founded in 1994 (formerly SR Pharma, renamed in 2007) that develops therapeutics based on short interfering RNA (siRNA), a technology that silences the expression of specific disease-causing genes at the post-transcriptional level. The company is focused on hematology, cardiovascular, and rare diseases, with a clinical pipeline led by Divesiran (SLN124) in Phase 2 for polycythemia vera and Zerlasiran (SLN360) for cardiovascular disease linked to elevated lipoprotein(a), alongside earlier-stage candidates including SLN548, SLN312, SLN365, and SLN098. As a clinical-stage biopharmaceutical firm with no marketed products, Silences business model centers on advancing its siRNA platform through R&D and strategic partnerships, generating value primarily through pipeline milestones and licensing rather than product sales.
- Divesiran Phase 2 polycythemia vera data readout approaches
- Zerlasiran Phase 2 Lp(a) cardiovascular trial results pending
- Cash runway narrows as small-cap siRNA developer faces dilution
| Net Income: -85.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: -1.13 > 0.02 and ΔFCF/TA -84.92 > 1.0 |
| NWC/Revenue: 10.0k% < 20% (prev 573.4%; Δ 9.45k% < -1%) |
| CFO/TA -0.57 > 3% & CFO -65.6m > Net Income -85.2m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 9.83 > 1.5 & < 3 |
| Outstanding Shares: last quarter (47.2m) vs 12m ago 200.1% < -2% |
| Gross Margin: 66.43% > 18% (prev 73.00%; Δ -6.57% > 0.5%) |
| Asset Turnover: 0.61% > 50% (prev 14.17%; Δ -13.55% > 0%) |
| Interest Coverage Ratio: -12.20 > 6 (EBIT TTM -78.7m / Interest Expense TTM 6.45m) |
| A: 0.80 (Total Current Assets 102.9m - Total Current Liabilities 10.5m) / Total Assets 115.1m |
| B: -5.02 (Retained Earnings -577.5m / Total Assets 115.1m) |
| C: -0.52 (EBIT TTM -78.7m / Avg Total Assets 150.2m) |
| D: 0.75 (Book Value of Equity 49.4m / Total Liabilities 65.7m) |
| Altman-Z'' = -13.82 = D |
| DSRI: 3.0 (Receivables 22.2m/16.8m, Revenue 921k/26.3m) |
| GMI: 1.10 (GM 73.00% / 66.43%) |
| AQI: 1.26 (AQ_t 0.09 / AQ_t-1 0.07) |
| SGI: 0.04 (Revenue 921k / 26.3m) |
| TATA: -0.17 (NI -85.2m - CFO -65.6m) / TA 115.1m) |
| Beneish M = -1.85 (Cap -4..+1) = B |
As of July 08, 2026, the stock is trading at USD 10.15 with a total of 617,654 shares traded. Over the past week, the price has changed by -5.93%, over one month by +62.92%, over three months by +81.25% and over the past year by +77.14%.
Current recommended Stop Loss: 9.20 (which is 9.4% or 1.3 ATR below the current price).
Silence Therapeutics has received a consensus analysts rating of 4.14. Therefore, it is recommended to buy SLN.
- StrongBuy: 3
- Buy: 3
- Hold: 0
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 29.2 | 187.4% |
P/S = 584.9435
P/B = 9.982
Revenue TTM = 921k USD
EBIT TTM = -78.7m USD
EBITDA TTM = -78.1m USD
Long Term Debt = 43.0k USD (estimated: total debt 136k - short term 93.0k)
Short Term Debt = 93.0k USD (from shortTermDebt, last quarter)
Debt = 136k USD (from shortLongTermDebtTotal, last quarter) (leases 136k already included)
Net Debt = -49.4m USD (calculated: Debt 136k - CCE 49.5m)
Enterprise Value = 441.4m USD (490.8m + Debt 136k - CCE 49.5m)
Interest Coverage Ratio = -12.20 (Ebit TTM -78.7m / Interest Expense TTM 6.45m)
EV/FCF = -3.39x (Enterprise Value 441.4m / FCF TTM -130.3m)
FCF Yield = -29.53% (FCF TTM -130.3m / Enterprise Value 441.4m)
FCF Margin = -14.1k% (FCF TTM -130.3m / Revenue TTM 921k)
Net Margin = -9.24k% (Net Income TTM -85.2m / Revenue TTM 921k)
Gross Margin = 66.43% ((Revenue TTM 921k - Cost of Revenue TTM 309k) / Revenue TTM)
Gross Margin QoQ = 72.28% (prev 64.71%)
Tobins Q-Ratio = 3.83 (Enterprise Value 441.4m / Total Assets 115.1m)
Interest Expense / Debt = 4.74k% (Interest Expense 6.45m / Debt 136k)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -62.2m (EBIT -78.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.94 (Total Current Assets 102.9m / Total Current Liabilities 20.8m)
Debt / Equity = 0.00 (Debt 136k / totalStockholderEquity, last quarter 49.4m)
Debt / EBITDA = 0.63 (negative EBITDA) (Net Debt -49.4m / EBITDA -78.1m)
Debt / FCF = 0.38 (negative FCF - burning cash) (Net Debt -49.4m / FCF TTM -130.3m)
Total Stockholder Equity = 70.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -56.70% (Net Income -85.2m / Total Assets 115.1m)
RoE = -121.7% (Net Income TTM -85.2m / Total Stockholder Equity 70.0m)
RoCE = -112.4% (out of range, set to none) (EBIT -78.7m / Capital Employed (Equity 70.0m + L.T.Debt 43.0k))
RoIC = -59.38% (negative operating profit) (NOPAT -62.2m / Invested Capital 104.7m)
WACC = 10.71% (E(490.8m)/V(490.9m) * Re(10.71%) + (debt cost/tax rate unavailable))
Discount Rate = 10.71% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 91.11 | Cagr: 76.20%
[DCF] Fair Price = unknown (Cash Flow -130.3m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.34 | # QB: 0
Revenue Correlation: -64.44 | Revenue CAGR: -62.74% | SUE: -0.17 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.11 | Chg30d=-10.00% | Revisions=-25% | Analysts=1
EPS next Quarter (2026-09-30): EPS=-0.10 | Chg30d=+0.00% | Revisions=+25% | Analysts=1
EPS current Year (2026-12-31): EPS=-0.40 | Chg30d=-2.56% | Revisions=-25% | GrowthEPS=+78.4% | GrowthRev=+496.5%
EPS next Year (2027-12-31): EPS=-0.39 | Chg30d=+0.00% | Revisions=+25% | GrowthEPS=+2.5% | GrowthRev=+37.9%